newstock.ai
← Back

AMGNAmgen

$377.35-1.34%Real quote · delayedBiopharmaPharma & biotech · 16 peers →

🏛️ Company factsSEC filings + FINRA official data

Annual revenue $36.8B · latest quarter up 9.5% YoY · profitable (FY net income $7.7B) · short activity below its recent average — bears covering.

FY revenue

$36.8B

2025-12

Latest Q YoY

+9.5%

Gross margin

18.6%

FY net income

$7.7B

Diluted EPS

$14.33

Short volume

41%

20d avg 51.4% · shorts covering

🐋 5%+ ownership filings (last 180d)

The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.

🎯 Market expectations

Expectation reliability High · 77/100

Nasdaq analyst consensus · the pre-news baseline

Next quarter (Sep 2026) consensus$5.69Estimate range $5.48 ~ $6.04 · 9 analystsRevisions (4w):2
History: actual vs consensusavg +11.3%
  • Jun 2026$6.29 vs $5.60+12.32%
  • Mar 2026$5.15 vs $4.73+8.88%
  • Dec 2025$5.29 vs $4.76+11.13%
  • Sep 2025$5.64 vs $5.00+12.8%

The takeaway

This company habitually beats by +11.3% — the next report has to clear that bar to count as good news.

Analyst estimates, not our forecast · not investment advice

What's moving this stock lately

4 direct · 2 2nd-order · 0 thematic

Ranked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)

🕰️ Price × news · engine report card

Drag to pan, scroll to zoom · real daily bars and volume

The 19 engine calls on this chart (hit / miss / pending) are Pro — price and volume only for nowvolume

📜 Call history (newest first

🔒 Pro only

19 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view

Sign up · free 7-day trial →
🔒 Pro only

Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.

Sign up · free 7-day trial →